Navigation Links
FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
Date:11/1/2007

f osteoporosis. Today, there are an estimated four to five million men in the U.S. who suffer from hypogonadism. Of this group, less than ten percent are currently receiving treatment with testosterone therapy.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R), VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(R); risks associated with contractual agreements, particular
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Mexico Supreme Court Accepts Petition To Review Mexico City Law Legalizing Abortion During First Three Months Gestation
2. Novartis files application with FDA for Zometa
3. Morepan to file new drug applications with the USFDA
4. Mini motor for micromedical applications
5. Perfusion bioreactor could enhance stem cell research and application in the future
6. Prostate Cancer Can Be Treated By Application Of LASER Technology
7. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
8. Venus Remedies Files 5th International Patent Application
9. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
10. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
11. New Drug Application Submitted for Investigational Antibiotic Doripenem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 In God’s Unstoppable Favor, ... as she writes an unforgettable story of how God ... life. The first black student to desegregate Evangeline Parish ... by some students, treated harshly by a few teachers, ... personal phone conversation with Dr. Martin Luther King, Jr. ...
(Date:5/26/2015)... 26, 2015 Dermatologic surgeons performed nearly ... according to survey results released today by the American ... cancer treatments and several cosmetic categories, 2014 totals were ... steady overall compared to 2013 figures. , For ... ranked as the most-performed procedure (3.08 million) by ASDS ...
(Date:5/26/2015)... York (PRWEB) May 26, 2015 The ... http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who were ... the litigation’s June 11th Science Day. According to an ... of Louisiana, on May 21st, topics to be addressed ... drug, the use of blood test based testing with ...
(Date:5/26/2015)... Rochester, MN (PRWEB) May 26, 2015 ... years of debilitating nosebleeds and fainting spells, four of ... even leading to cardiac arrest. , Though she ... transfusion, she continues to dedicate her time to increasing ... mission. , “Had there been awareness, we could have ...
(Date:5/26/2015)... May 26, 2015 Last week, ... Mexico patients with MRI, Ultrasound, and CT services—was ... American College of Radiology. The center is now ... , In order to be eligible for ... of qualifications including personnel qualifications, adequacy of facility ...
Breaking Medicine News(10 mins):Health News:Grace Sibley Releases Second Book, God's Unstoppable Favor 2Health News:New ASDS Survey: 9.5 Million Treatments Performed in 2014 2Health News:New ASDS Survey: 9.5 Million Treatments Performed in 2014 3Health News:New ASDS Survey: 9.5 Million Treatments Performed in 2014 4Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 3Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 4Health News:Rochester Woman Brings Awareness to Genetic Disease 2
... it as been found in a study that drinking coffee may ... consumption should be moderate. Its moderate consumption every day may lower ... studies in US had linked drinking more than two cups of ... chronic liver disease. ,This new study by Harvard School ...
... Australian scientists are of the opinion that older adults ... heart disease. // ,The researchers at the ... a high risk than those without asthma to suffer ... and cancer,The study’s lead author Dr. Robert Adams ...
... government is facing accusation from the Victorian Opposition for ... ,Reports are rife that almost one in ... of being discharged from the hospital, necessitating a re-admission. ... Government about mental health shortfalls, during the previous year. ...
... the socioeconomic status of an individual that determines the ... published in the March 15, 2006 issue of CANCER, ... ,The study found that education, community poverty, and income ... outcomes as did age, disease stage, and treatment method. ...
... public display of their affection here on Valentine's Day would ... some young lovers. ,Youngsters have got over the initial ... lovers by the Akhil Bharatiya Vidhyarthi Parishad (ABVP), the Vishwa ... move is now being welcomed by courting couples, who are ...
... their telephonic conversations to a minimal level owing to the ... federal bureau for radiation protection (BfS) in Salzgitter says people ... station in an area of their home where they do ... is a good example. ,The cordless telephones, which commonly ...
Cached Medicine News:
(Date:5/26/2015)... DIEGO , May 26, 2015 ... developing targeted therapeutic devices to address infectious diseases ... Joyce , Chief Executive Officer, will present at ... Thursday, May 28th.  Details of Aethlon Medical,s presentation ... Investor Conference Date: , Thursday, May 28, 2015Time: ...
(Date:5/26/2015)... , May 26, 2015 ViiV ... Inc. (CHAI) announced today that Aurobindo Pharma has submitted ... for Tentative Approval, to the Food and Drug Administration ... first ANDA for a generic version of dolutegravir, less ... for sale in the United States ...
(Date:5/26/2015)... Mass. , May 26, 2015  Respiratory ... 62 nd Annual Meeting of the Japanese ... of monitoring patient respiration in hospitals miss critical ... risks to patients. The findings conclude that respiratory ... Respiratory Motion, Inc. more consistently protects patients than ...
Breaking Medicine Technology:Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 2Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 3Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 3ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 5ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 6ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 7Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 2Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 3Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 4Eight Studies Find Capnography, Pulse Oximetry Can Leave Patients at Risk for Life-Threatening Respiratory Depression 5
... 2010 HeartWare International, Inc. (Nasdaq: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... December 7, 2010 at 9:00 a.m. Pacific Time (noon, ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... the UK has completed review of the Clinical Trial Application ... 673 for genetically-defined cancers.  The company expects to initiate a ... "BMN 673 has been proven to be highly active ...
Cached Medicine Technology:HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers 2MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: